Companies:
49,817
Total Market Cap:
139333776081124.71
Global Rank
#8804
Country Rank
#24
Market Cap
1.16 B
Price
9.35
Change (%)
0.56%
Volume
318,450
Neuren Pharmaceuticals Limited's latest marketcap:
1.16 B
As of 07/05/2025, Neuren Pharmaceuticals Limited's market capitalization has reached $1.16 B. According to our data, Neuren Pharmaceuticals Limited is the 8804th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.16 B |
| Revenue (ttm) | 142.02 M |
| Net Income (ttm) | 93.04 M |
| Shares Out | 124.49 M |
| EPS (ttm) | 0.71 |
| Forward PE | 108.41 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/29/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Neuren Pharmaceuticals Limited's yearly market capitalization.
Neuren Pharmaceuticals Limited has seen its market value grow from A$191.43 M to A$1.16 B since 2014, representing a total increase of 508.27% and an annual compound growth rate (CAGR) of 18.74%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | A$1.16 B | 11.34% | 8804 |
| 12/31/2024 | A$1.59 B | -50.04% | 8896 |
| 12/29/2023 | A$3.18 B | 217.33% | 5341 |
| 12/30/2022 | A$1 B | 110.88% | 10354 |
| 12/31/2021 | A$474.89 M | 222.46% | 15662 |
| 12/31/2020 | A$147.27 M | -40.72% | 19885 |
| 12/31/2019 | A$248.42 M | 77.14% | 15419 |
| 12/31/2018 | A$140.24 M | -56.97% | 17324 |
| 12/29/2017 | A$325.89 M | 215.94% | 13570 |
| 12/30/2016 | A$103.15 M | -47.76% | 17368 |
Company Profile
Neuren Pharmaceuticals Limited
Company Overview: Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of drugs for neurological disorders. Founded in 2001 and headquartered in Camberwell, Australia, the company focuses on innovative treatments for rare and complex neurological conditions.
Key Developments & Pipeline
- DAYBUE (trofinetide): Approved for the treatment of Rett syndrome in adults and pediatric patients aged 2 years and older. Currently in Phase 2 clinical trials for Fragile X syndrome.
- NNZ-2591:
- Completed Phase 2 trials for Phelan-McDermid syndrome.
- In Phase 2 trials for Angelman syndrome and Pitt Hopkins syndrome.
- In preclinical development for Prader-Willi syndrome.
Frequently Asked Questions
-
What is Neuren Pharmaceuticals Limited's (ASX-NEU) current market cap?As of 07/05/2025, Neuren Pharmaceuticals Limited (including the parent company, if applicable) has an estimated market capitalization of $1.16 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Neuren Pharmaceuticals Limited (ASX-NEU) rank globally by market cap?Neuren Pharmaceuticals Limited global market capitalization ranking is approximately 8804 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.